GENFIT S.A. stock is down -4.44% since 30 days ago. The next earnings date is Apr 11, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 February’s closed higher than January.
Genfit S.A. discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. Elafibranor is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!